Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer
Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in a fireside chat at the Raymond James LILRB/ILT Symposium on April 26, 2022, at 1:00 pm ET. The symposium will focus on 'Myeloid Checkpoint' therapeutics in cancer. Jounce is dedicated to developing innovative cancer immunotherapies through a biomarker-driven approach. Its lead program, JTX-8064, targets immune-suppressive tumor-associated macrophages, while other candidates like vopratelimab and pimivalimab are in various stages of clinical trials. For more information, visit www.jouncetx.com.
- None.
- None.
CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer taking place virtually on Tuesday, April 26, 2022 at 1:00 pm ET.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. JTX-8064 is currently being investigated alone and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, in one monotherapy and seven combination indication-specific expansion cohorts in the Phase 1/2 INNATE trial and is currently enrolling patients with advanced solid tumors in the Phase 2 portion of the study. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to GS-1811 (formerly JTX-1811), a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
Investor and Media Contacts:
Eric Laub
Jounce Therapeutics, Inc.
+1-857-259-3853
elaub@jouncetx.com
FAQ
When is Jounce Therapeutics participating in the Raymond James Symposium?
What is the focus of the Raymond James LILRB/ILT Symposium?
What is Jounce Therapeutics' lead program?
What clinical trials is Jounce Therapeutics currently involved in?
What is the stock symbol for Jounce Therapeutics?
